Home / Healthcare/ AbbVie looks beyond Humira with $ 63 billion deal for Botox-maker Allergan

AbbVie looks beyond Humira with $ 63 billion deal for Botox-maker Allergan


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 3 July 2019 00:00

Facebook

 


  • The world’s top-selling drug brought in sales of $ 20 billion last year

Reuters: Drugmaker AbbVie Inc. said on Tuesday it would acquire Allergan Plc for about $ 63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses US patent protection.

AbbVie has long been under pressure to diversify its portfolio and its shares have lost more than a third of their value since January 2018 over concerns about Humira.

The world’s top-selling drug brought in sales of $ 20 billion last year. But it now faces competition from cheaper versions in Europe and a 2023 expiration of its patents in the United States, by far the most profitable market.

AbbVie Chief Executive Richard Gonzalez said the company was able to buy Allergan because of the massive amount of cash that Humira generates. A US corporate tax overhaul under the Trump administration, which helped companies bring back revenue earned overseas, also helped, he said.

“Humira is buying the assets that replace it over the long term,” said Gonzalez, who plans to lead the combined company and remain chairman and CEO through 2023.

Chief among those assets is Allergan’s Botox, a purified form of botulinum toxin that paralyzes muscles, smoothing frown lines and wrinkles in the forehead and around the eyes. The injection is also approved to treat chronic migraine headaches, overactive bladder and other medical uses.Botox had 2018 sales of about $ 3.6 billion, with $ 1.55 billion coming from cosmetic uses. When used as a cosmetic treatment, patients must pay for Botox out of pocket, buffering it from the pricing pressure that health insurers and government health agencies have put on prescription medicines.

AbbVie sees particular opportunity in the aesthetics market, which Gonzalez described as “highly underpenetrated” and primed to double by 2025, driven by increasing use by younger consumers looking to head off wrinkles before they start.

In addition, Gonzalez said he does not expect a biosimilar version of Botox “for a long, long time, if ever.”Both therapeutic and cosmetic Botox are expected to keep growing, with analysts forecasting total 2019 sales of $ 3.9 billion and reaching nearly $ 6 billion by 2025, according to Refinitiv data.

“We believe the increasing concern about AbbVie’s growth potential following the US Humira biosimilar competition in 2023 will be partially alleviated with the increased portfolio of assets that Allergan brings,” said Morningstar analyst Damien Conover.The deal, coming months after Bristol-Myers Squibb Co agreed to buy Celgene Corp for $ 74 billion, also highlights renewed interest in major acquisitions by the pharmaceutical industry.

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Expand employer-backed childcare to close the gender gap in Sri Lanka

Friday, 19 July 2019

In Sri Lanka, women’s formal workforce participation is at only 36%, compared with 75% for men. Sri Lanka could raise its gross domestic product by as much as 20% in the long-run by closing the gender gap in the workforce, according to one estimate


Who should be our next president?

Friday, 19 July 2019

After the recent terrorist attacks and the subsequent violence unleashed against innocent Muslims by racists, Sri Lankans are searching for a leader who can save the country. Many have lost faith in the leaders, due to the breakdown in the security a


The messed-up lives

Friday, 19 July 2019

It can be seen that there is a serious mess-up not only in the State and the social system in Sri Lanka, but also in the lives of the people. People of Sri Lanka are having smiling faces, yet those who live happily are very rare. You will find that u


Reimagining our reality: the last best hope for us?

Friday, 19 July 2019

Imagination can be a powerful tool for shaping everyday reality. We use it to construct everything from the mundane to the mystic. A down-to-earth example would be our subscription to the idea of the intrinsic value and worth of every human being. I


Columnists More